VESPINA LIFESCIENCES
Vespina Lifesciences plans to develop to proof-of-concept a potential compound with the potential to treat certain types of inflammatory diseases including pulmonary indications with poor therapeutic options as well as non-pulmonary inflammatory diseases. The compound was originally discovered and characterized at Denmark-based Neuprozyme Therapeutics ApS. There are upwards of 70,000 patients newly diagnosed with bronchiectasis in the US every year as more than half of the 16+ million patients diagnosed with COPD in the US likely also have concurrent bronchiectasis. There are no approved treatments that specifically address the underlying mechanism of disease.
VESPINA LIFESCIENCES
Industry:
Biopharma Biotechnology Health Care Life Science
Address:
Newark, Delaware, United States
Country:
United States
Status:
Active
Total Funding:
0
Similar Organizations
Genelabs Technologies
Genelabs Technologies is a biopharmaceutical company engaged in the R&D of therapeutics for the treatment of infectious diseases.
Investors List
TVM Capital Life Science
TVM Capital Life Science investment in Venture Round - Vespina Lifesciences